Concepedia

Lorna Hopcroft

LH

Statistics

Publications

7

Citations

277

H-Index

7

Active since

2012

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

Lorna Hopcroft is an author at AstraZeneca (United States) specializing in cancer therapeutics, cancer research, and tumor biology.

ORCID

Top concepts

Publications per year

2012–2024

7

Publications

7

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft et al. · Oncotarget · 2017 · 149 citations · Full text

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

Frederick W. Goldberg, Jason G. Kettle, Gillian M. Lamont et al. · Journal of Medicinal Chemistry · 2022 · 53 citations · Full text

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

Thomas G. Hayhow, Beth Williamson, Mandy Lawson et al. · Communications Biology · 2024 · 19 citations · Full text

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

Cath Eberlein, Stuart C. Williamson, Lorna Hopcroft et al. · British Journal of Cancer · 2024 · 17 citations · Full text

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson et al. · npj Breast Cancer · 2023 · 15 citations · Full text

, , +18

Rows per page

1–5 of 7